Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INP103 intranasal L-dopa/placebo study in Parkinson's disease OFF episodes
ACTRN12618000427279Phase 2Completed
- Sponsor
- Clinical Network Services
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dihydroergotamine in Parkinson's disease (PD) (2 arms), sponsored by Clinical Network Services. Primary endpoint: Safety and tolerability of POD L-dopa. Started May 2018; status: completed.
02
Drugs
dihydroergotamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12618000427279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000427279.